[1] Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol,2012,56(4): 952-964. [2] Ooi K, Shiraki K, Morishita Y, et al. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med,2005,15(4): 655-660. [3] Habib A, Mihas AA, Abou SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhosis. Clin Gastroenterol Hepatol,2005,3(3): 286-291. [4] Mohammad G, Ali R, Abbas H, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepat Mon, 2010, 10(4): 285-288. [5] Makarov VK, Khomeriki SG. Serum lipids as biochemical manifestations of hepatic alcoholic, viral, and mixed viral and alcoholic lesion. Klin Lab Diagn,2007,5(5): 17-19. [6] Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat,2006,13(1): 56-61. [7] Lech C, Lukasz S, Anatol P, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med,2014,14(4): 417-421. [8] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版).中国循环杂志,2016,31(10):937-953. [9] Luisa S, Davide N, Graziella P, et al. Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scand J Gastroenterol, 2015, 50(3): 347-354. [10] Wang B, Tontonoz P. Liver X receptors in lipid signaling and membrane homeostasis. Nature reviews. Endocrinology,2018,14(8): 452-463. [11] Markus T, Florian R, Vanessa S, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol,2020,73(1): 113-120. [12] Pirillo A, Catapano AL, Norata GD. HDL in infectious diseases and sepsis. Handb Exp Pharmacol,2015,224: 483-508. [13] Kunal S, Bikash S, Subhraprakash P, et al. Lipid profile in alcoholic and nonalcoholic patients of chronic liver disease-a comparative and analytical study in a rural-based tertiary care center. J Assoc Physicians India, 2019, 67(4): 22-24. [14] Kabbany ZA, Hamza RT, Ibrahim SA, et al. Dyslipidemia and hyperinsulinemia in children and adolescents with chronic liver disease: relation to disease severity. Int J Adolesc Med Health, 2014, 26(2): 195-201. [15] Graziella P, Luisa S, Simona M, et al. Abnormalities of lipoprotein levels in liver cirrhosis: clinical relevance. Dig Dis Sci, 2018, 63(1): 16-26. [16] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol,2017,67(4): 862-873. [17] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议(2019年修订版).实用肝脏病杂志, 2019, 22(6): 787-792. [18] Kwarteng JK, Owusu L, Afihene M, et al. Lowered serum triglyceride levels among chronic hepatitis B-infected patients in Ghana. J Sci Technol, 2012, 32(3): 1-10. [19] Vere CC, Streba CT, Streba L, et al. Lipid serum profile in patients with viral liver cirrhosis. Med Princ Pract,2012,21(6): 566-568. [20] Carla M, Renata P, Mauricio P, et al. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol, 2006, 21(8): 1236-1239. |